Delivery Order SPE2DB24D2106-SPE2DB25FAURF
Award Date
2/25/25
Potential Completion Date
2/26/25
Potential Value
$2.3K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,605.38 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a prescription medication. The award is not associated with any set-aside designations. DMS Pharmaceutical Group holds a significant $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This federal contract award issued by the Defense Logistics Agency (DLA) is a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $2,537.17 contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized prescription medication. DMS Pharmaceutical Group holds a significant $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue delivery...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $1,440.48 contract is for the delivery of Quillivant XR 25 mg/5 ml suspension in a 150 ml bottle. The contract has an ultimate completion date of March 3, 2025 and is not associated with any set-aside designation. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 Indefinite Delivery Contract...
This is a delivery order contract (SPE2DB20D6037|SPE2DB25FTUE9) awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,051.36 firm fixed-price contract is for the supply of Quillivant XR 25 mg/5 ml suspension, a specialized pharmaceutical product. DMS Pharmaceutical Group Inc. holds a $499,999,999 single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is for the delivery of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The $5,393.20 firm fixed-price delivery order was issued by the Defense Logistics Agency (DLA) under the SPE2DB24 indefinite delivery contract, which has a ceiling value of up to $499,999,999 and runs through December 31, 2025. This single-award IDC allows the DLA to issue delivery orders for a...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of Quillivant XR 25 mg/5 ml suspension (120 ml) and has a ceiling value of $2,280.55. The contract has a period of performance through July 16, 2024. The contract is issued under the DLA's SPE2DB pharmaceutical prime vendor program, a single-award indefinite delivery contract (IDC) valued...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The contract has a ceiling value of $2,371.46 and a final completion date of July 31, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $2,973.05, is a firm fixed-price delivery order for Quillivant XR 25 mg/5 ml suspension, a pharmaceutical product. The contract has an ultimate completion date of December 5, 2024. DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a range of branded and generic...
This federal contract award issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of Quillivant XR 25 mg/5 ml suspension in 120 ml bottles. The contract is a firm fixed-price delivery order with a ceiling value of $1,631.03 and a completion date of October 29, 2024. DMS Pharmaceutical Group Inc. is the prime contractor and this order is issued under a larger $499,999,999 Indefinite Delivery Contract (IDC) the company...
This is a federal contract award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business. The contract is for the delivery of a pharmaceutical product, Quillivant XR 25 mg/5 ml suspension, with a ceiling value of $2,076.13. The contract has a firm fixed-price pricing type and is a delivery order with an ultimate completion date of April 5, 2024. This award appears to be part of a larger indefinite delivery contract (IDV) that DMS...